新辅助化疗在局部晚期子宫颈癌治疗中的应用  

Application of neoadjuvant chemotherapy in treatment of locally advanced cervical cancer

作　　者：王鸽 孙立新[2] Wang Ge;Sun Lixin(Graduate School of Shanxi Medical University,Taiyuan 030001,China;Department of Gynecology 2,Shanxi Province Cancer Hospital,Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences,Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China)

机构地区：[1]山西医科大学研究生学院,太原030001 [2]山西省肿瘤医院中国医学科学院肿瘤医院山西医院山西医科大学附属肿瘤医院妇二科,太原030013

出　　处：《肿瘤研究与临床》2022年第3期230-233,共4页Cancer Research and Clinic

摘　　要：局部晚期子宫颈癌(LACC)是指局限于子宫颈或仅累及盆腔局部的大病灶子宫颈癌,具有肿瘤体积大、局部控制困难、手术难度较大、术后易复发转移等特点,5年总生存率约为50%。新辅助化疗(NACT)可降低患者复发和死亡的风险,同时降低术后放射治疗的概率,避免放疗带来的卵巢功能受损。但也有研究显示NACT对于LACC的总生存无益,甚至干扰术后病理诊断等。因此对于NACT在临床上的应用仍有争议。文章对NACT在LACC中的应用现状进行综述。Locally advanced cervical cancer(LACC)refers to cervical cancer with large lesions confined to the cervix or only involving pelvic.It is characterized by large tumor volume,difficult local control,difficult operation,easy recurrence and metastasis after operation,and its 5-year overall survival rate is about 50%.Neoadjuvant therapy(NACT)reduces the risk of recurrence and death in patients,reduces the probability of postoperative radiotherapy,and avoids the ovarian dysfunction caused by radiotherapy.However,some studies have shown that NACT is not beneficial to the overall survival of LACC and may even interfere with postoperative pathological diagnosis.Therefore,the clinical application of NACT is still controversial.This article reviews the application of NACT in LACC.

关 键 词：宫颈肿瘤 新辅助治疗 放射疗法 药物疗法 联合 

分 类 号：R737.33[医药卫生—肿瘤]